Livingston Group Asset Management CO operating as Southport Capital Management Sells 254 Shares of Becton Dickinson and Co (NYSE:BDX)

Livingston Group Asset Management CO operating as Southport Capital Management cut its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,095 shares of the medical instruments supplier’s stock after selling 254 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Becton Dickinson and were worth $570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the business. AE Wealth Management LLC raised its holdings in Becton Dickinson and by 19.4% during the 3rd quarter. AE Wealth Management LLC now owns 5,127 shares of the medical instruments supplier’s stock valued at $1,297,000 after buying an additional 833 shares during the period. Russell Investments Group Ltd. increased its position in Becton Dickinson and by 0.6% during the third quarter. Russell Investments Group Ltd. now owns 696,570 shares of the medical instruments supplier’s stock valued at $174,650,000 after acquiring an additional 4,237 shares during the last quarter. MAI Capital Management increased its position in Becton Dickinson and by 43.4% during the second quarter. MAI Capital Management now owns 3,215 shares of the medical instruments supplier’s stock valued at $810,000 after acquiring an additional 973 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA raised its stake in shares of Becton Dickinson and by 0.8% in the third quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 6,366 shares of the medical instruments supplier’s stock valued at $1,610,000 after acquiring an additional 51 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Becton Dickinson and by 7.6% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 63,248 shares of the medical instruments supplier’s stock valued at $15,999,000 after acquiring an additional 4,487 shares during the period. Institutional investors and hedge funds own 84.46% of the company’s stock.

In other news, CEO Vincent A. Forlenza sold 11,626 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $265.57, for a total transaction of $3,087,516.82. Following the completion of the sale, the chief executive officer now owns 225,393 shares of the company’s stock, valued at $59,857,619.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vincent A. Forlenza sold 33,365 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $271.28, for a total value of $9,051,257.20. Following the completion of the sale, the chief executive officer now owns 254,312 shares of the company’s stock, valued at approximately $68,989,759.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,231 shares of company stock valued at $24,787,690. 0.12% of the stock is owned by corporate insiders.

Several equities research analysts have recently weighed in on BDX shares. Morgan Stanley increased their target price on shares of Becton Dickinson and from $261.00 to $287.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. JPMorgan Chase & Co. increased their target price on shares of Becton Dickinson and from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. Stifel Nicolaus increased their target price on shares of Becton Dickinson and from $275.00 to $295.00 and gave the company a “buy” rating in a research note on Monday, December 16th. KeyCorp reduced their target price on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Finally, Barclays downgraded shares of Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 target price on the stock. in a research note on Wednesday, January 8th. Six investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $277.70.

Shares of BDX traded down $2.01 during midday trading on Thursday, hitting $275.29. The stock had a trading volume of 24,067 shares, compared to its average volume of 1,009,192. Becton Dickinson and Co has a 1 year low of $221.47 and a 1 year high of $279.62. The firm has a market cap of $74.64 billion, a PE ratio of 23.57, a price-to-earnings-growth ratio of 1.97 and a beta of 1.07. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.18 and a quick ratio of 0.72. The stock’s 50 day moving average is $267.92 and its 200 day moving average is $256.09.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. The firm had revenue of $4.58 billion for the quarter, compared to analysts’ expectations of $4.57 billion. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.93 earnings per share. As a group, equities research analysts expect that Becton Dickinson and Co will post 12.57 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Tuesday, December 10th were issued a dividend of $0.79 per share. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date was Monday, December 9th. This represents a $3.16 dividend on an annualized basis and a yield of 1.15%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Differences Between Momentum Investing and Long Term Investing

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.